Journal
MEDICINAL RESEARCH REVIEWS
Volume 42, Issue 5, Pages 1739-1780Publisher
WILEY
DOI: 10.1002/med.21891
Keywords
antiviral; drug discovery; infectious disease; natural product; Zika virus
Categories
Funding
- MOE Tier 2 [MOE2017-T2-1-078, MOE2017-T2-2-014, NRF-CRP21-2018-0004]
Ask authors/readers for more resources
Zika virus, transmitted by mosquitoes, can cause severe neurological implications and fetal abnormalities, and there are currently no approved therapeutic drugs or vaccines. However, recent research on natural products has shown potential for developing antiviral drugs.
Zika virus (ZIKV) is an arbovirus belonging to the flavivirus genus and is transmitted in Aedes mosquito vectors. Since its discovery in humans in 1952 in Uganda, ZIKV has been responsible for many outbreaks in South America, Africa, and Asia. Patients infected with ZIKV are usually asymptomatic; mild symptoms include fever, joint and muscle pain, and fatigue. However, severe infections may have neurological implications, such as Guillain-Barre syndrome and fetal microcephaly. To date, there are no existing approved therapeutic drugs or vaccines against ZIKV infections; treatments mainly target the symptoms of infection. Preventive measures against mosquito breeding are the main strategy for limiting the spread of the virus. Antiviral drug research for the treatment of ZIKV infection has been rapidly developing, with many drug candidates emerging from drug repurposing studies, and compound screening. In particular, several studies have demonstrated the potential of natural products as antivirals for ZIKV infection. Hence, this paper will review recent advances in natural products in ZIKV antiviral drug discovery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available